Dr. Gary Phillips was named Chief Business Officer of Anaveon in May 2022. Dr. Phillips has three decades of experience across healthcare. He was President & CEO of OrphoMed from 2018 to 2022. Before OrphoMed, Dr. Phillips worked at Mallinckrodt Pharmaceuticals, where he was EVP & Chief Strategy Officer as well as President, Autoimmune & Rare Diseases. He was the Head of Global Health & Healthcare at the World Economic Forum. He served in senior executive roles at Reckitt Benckiser Pharmaceuticals, Bausch & Lomb, Merck Serono, Novartis, and Wyeth. He earned a BA in Biochemistry summa cum laude from the University of Pennsylvania’s College of Arts & Sciences, an MBA from its Wharton School, and an MD Alpha Omega Alpha from its School of Medicine. Dr. Phillips practiced as a U.S. Navy general medical officer. He currently serves as Chairman of the Board of Nanobiotix as well as a Director on the Boards of Aldeyra Therapeutics and Rheon Medical SA.
Likes
Share It 
